Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorRIGATO, Paula Ordonhez-
dc.contributor.authorMACIEL JR., Milton-
dc.contributor.authorGOLDONI, Adriana Leticia-
dc.contributor.authorPIUBELLI, Orlando Guerra-
dc.contributor.authorORII, Noemia Mie-
dc.contributor.authorMARQUES, Ernesto Torres-
dc.contributor.authorAUGUST, Joseph Thomas-
dc.contributor.authorDUARTE, Alberto Jose da Silva-
dc.contributor.authorSATO, Maria Notomi-
dc.identifier.citationPLOS ONE, v.7, n.2, article ID e31608, 11p, 2012-
dc.description.abstractInfants born to HIV-infected mothers are at high risk of becoming infected during gestation or the breastfeeding period. A search is thus warranted for vaccine formulations that will prevent mother-to-child HIV transmission. The LAMP/gag DNA chimeric vaccine encodes the HIV-1 p55gag fused to the lysosome-associated membrane protein-1 (LAMP-1) and has been shown to enhance anti-Gag antibody (Ab) and cellular immune responses in adult and neonatal mice; such a vaccine represents a new concept in antigen presentation. In this study, we evaluated the effect of LAMP/gag DNA immunization on neonates either before conception or during pregnancy. LAMP/gag immunization of BALB/c mice before conception by the intradermal route led to the transfer of anti-Gag IgG1 Ab through the placenta and via breastfeeding. Furthermore, there were an increased percentage of CD4+ CD25+ Foxp3+ T cells in the spleens of neonates. When offspring were immunized with LAMP/gag DNA, the anti-Gag Ab response and the Gag-specific IFN-gamma-secreting cells were decreased. Inhibition of anti-Gag Ab production and cellular responses were not observed six months after immunization, indicating that maternal immunization did not interfere with the long-lasting memory response in offspring. Injection of purified IgG in conjunction with LAMP/gag DNA immunization decreased humoral and cytotoxic T-cell responses. LAMP/gag DNA immunization by intradermal injection prior to conception promoted the transfer of Ab, leading to a diminished response to Gag without interfering with the development of anti-Gag T- and B-cell memory. Finally, we assessed responses after one intravenous injection of LAMP/gag DNA during the last five days of pregnancy. The intravenous injection led to in utero immunization. In conclusion, DNA vaccine enconding LAMP-1 with Gag and other HIV-1 antigens should be considered in the development of a protective vaccine for the maternal/fetal and newborn periods.-
dc.description.sponsorshipMinisterio da Saude do Brasil [914BRA1101]-
dc.description.sponsorshipFundacao de Amparo a Pesquisa de Sao Paulo (FAPESP) [2004/14443-2]-
dc.description.sponsorshipLaboratorio de Investigacao Medica, Unidade 56 do Hospital das Clinicas da Faculdade de Medicina de Sao Paulo (FMUSP-HC/LIM-56)-
dc.relation.ispartofPlos One-
dc.subject.otherhypersensitivity response-
dc.subject.otherhiv-1 transmission-
dc.subject.otherallergen exposure-
dc.subject.otherii compartment-
dc.titleMaternal LAMP/p55gagHIV-1 DNA Immunization Induces In Utero Priming and a Long-Lasting Immune Response in Vaccinated Neonates-
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCE-
dc.subject.wosMultidisciplinary Sciences-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion- JR., Milton:USN, Enter Dis Dept, Infect Dis Directorate, Med Res Ctr, Silver Spring, MD USA-, Adriana Leticia:Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, Dept Dermatol,LIM 56, Sao Paulo, Brazil-, Orlando Guerra:Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, Dept Dermatol,LIM 56, Sao Paulo, Brazil-, Ernesto Torres:Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA-, Joseph Thomas:Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA-
hcfmusp.publisher.citySAN FRANCISCO-
hcfmusp.relation.referenceArruda LB, 2006, J IMMUNOL, V177, P2265-
hcfmusp.relation.referenceBecquet R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007397-
hcfmusp.relation.referenceBOGEN B, 1993, EMBO J, V12, P357-
hcfmusp.relation.referenceChasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486-
hcfmusp.relation.referencede Alencar BCG, 2009, INFECT IMMUN, V77, P4383, DOI 10.1128/IAI.01459-08-
hcfmusp.relation.referenceDe Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x-
hcfmusp.relation.referencede Brito CA, 2009, IMMUNOTHERAPY, V1, P883, DOI [10.2217/imt.09.38, 10.2217/IMT.09.38]-
hcfmusp.relation.referenceFusaro AE, 2002, INT ARCH ALLERGY IMM, V127, P208, DOI 10.1159/000053865-
hcfmusp.relation.referenceFusaro AE, 2007, IMMUNOLOGY, V122, P107, DOI 10.1111/j.1365-2567.2007.02618.x-
hcfmusp.relation.referenceFusaro AE, 2009, IMMUNOLOGY, V128, pe541, DOI 10.1111/j.1365-2567.2008.03028.x-
hcfmusp.relation.referenceGerdts V, 2000, NAT MED, V6, P929-
hcfmusp.relation.referenceGoldoni AL, 2011, IMMUNOBIOLOGY, V216, P505, DOI 10.1016/j.imbio.2010.08.007-
hcfmusp.relation.referenceHassett DE, 1997, J VIROL, V71, P7881-
hcfmusp.relation.referenceHorwitz DA, 2008, EUR J IMMUNOL, V38, P912, DOI 10.1002/eji.200738109-
hcfmusp.relation.referenceJohn GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918-
hcfmusp.relation.referenceJONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116-
hcfmusp.relation.referenceKanwar B, 2010, CURR OPIN HIV AIDS, V5, P151, DOI 10.1097/COH.0b013e328335c0c1-
hcfmusp.relation.referenceKim J, 2009, J IMMUNOL, V182, P2583, DOI 10.4049/jimmunol.0803247-
hcfmusp.relation.referenceLohman-Payne B, 2010, CLIN PERINATOL, V37, P787, DOI 10.1016/j.clp.2010.08.005-
hcfmusp.relation.referenceManickan E, 1997, J CLIN INVEST, V100, P2371, DOI 10.1172/JCI119777-
hcfmusp.relation.referenceMarques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200-
hcfmusp.relation.referenceVictor JR, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-11-
hcfmusp.relation.referenceOkuda K, 2001, J IMMUNOL, V167, P5478-
hcfmusp.relation.referenceRigato PO, 2010, VIROLOGY, V406, P37, DOI 10.1016/j.virol.2010.06.050-
hcfmusp.relation.referenceRigato PO, 2009, IMMUNOTHERAPY, V1, P141, DOI [10.2217/1750743X.1.1.141, 10.2217/1750-743X.1.1.141]-
hcfmusp.relation.referenceRinaldi M, 2006, VACCINE, V24, P4586, DOI 10.1016/j.vaccine.2005.08.030-
hcfmusp.relation.referenceSedegah M, 2003, J IMMUNOL, V171, P3148-
hcfmusp.relation.referenceSiegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004-
hcfmusp.relation.referenceSiegrist CA, 1998, EUR J IMMUNOL, V28, P4138, DOI 10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.3.CO;2-C-
hcfmusp.relation.referenceUNAIDS, 2009, AIDS EP UPD-
hcfmusp.relation.referenceVictor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39-
hcfmusp.relation.referenceXin Ke-Qin, 2002, Biological Procedures Online, V3, P91, DOI 10.1251/bpo27-
hcfmusp.relation.referenceXin KQ, 2003, J GENE MED, V5, P438, DOI 10.1002/jgm.356-
hcfmusp.remissive.sponsorshipMinistério da Saúde-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDT
Departamento de Dermatologia - FM/MDT

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial

Artigos e Materiais de Revistas Científicas - LIM/56
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências

Files in This Item:
File Description SizeFormat 
art_RIGATO_Maternal_LAMP_p55gagHIV_1_DNA_Immunization_Induces_In_2012.PDFpublishedVersion (English)1.03 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.